Peptech celebrates as US anti-TNF patents secured
13 September, 2002 by Graeme O'NeillSydney biotech company and antibody specialist Peptech has secured a prize patent for its anti-TNF antibody technology in the United States, the world's most lucrative market.
EpiTan names ex-CSL czar as director
13 September, 2002 by Melissa TrudingerMelbourne-based EpiTan has appointed ex-CSL general manager Stanley McLiesh as a non-executive director.
GTG joins project to bring wallaby back from the brink
13 September, 2002 by Melissa TrudingerMelbourne biotech company Genetic Technologies has become the sponsor of one of Victoria's most endangered animals, the brush-tailed rock wallaby.
Agenix profits up as sales soar
13 September, 2002 by Pete YoungOne of Australia oldest biotechs, Agenix Ltd, has produced extraordinary across-the-board results on booming sales of its blood clot diagnostic and infant hygiene products.
Cytopia unveils new HQ
12 September, 2002 by Melissa TrudingerBrand new labs on the fifth floor of the Baker Medical Research Institute have become the new home for Melbourne biotech company Cytopia.
Contract business boosts Progen revenue
12 September, 2002 by Pete YoungProgen Industries has posted a 58 per cent year-on-year revenue gain, due largely to the performance of its life sciences business, particularly its contract drug manufacturing unit.
Peplin rights issue bucks the trend
12 September, 2002 by Pete YoungListed company Peplin Biotech is proving that requests for fresh funds by young biotechs whose products are far from market-ready aren't receiving an automatic thumbs down from investors.
Axon posts loss as revenue slumps
12 September, 2002 by Pete YoungFormer share market favorite Axon Instruments has posted after-tax losses of $8.8 million on falling revenues for the half year to June 30.
Bio-septic system offers relief for the effluent society
11 September, 2002 by Graeme O'NeillOut of sight, out of mind, and far too often, out of order - that malodorous monster, the septic tank, lurks just below the ground in the back yards of more than 450,000 homes around Australia's eastern seaboard, from Queensland to Victoria. Another 200,000 households around New Zealand are unsewered.
Benitec hires management, gears up to commercialise
11 September, 2002 by Melissa TrudingerBrisbane biotech Benitec has added a managing director and a commercial director to its senior management team, as it prepares to expand its commercialisation activities.
New deal suggests FDA approval closer for Gradipore
11 September, 2002 by Iain ScottFDA approval for Sydney-based separation technology company Gradipore has come a step closer, after the signing of a new agreement with Canadian hyperimmune product specialist Cangene.
Norwood Abbey raises $4.13 million
10 September, 2002 by Melissa TrudingerNorwood Abbey has raised $4.13 million in a placement to institutional and professional investors.
Solbec hires Bioscience to grow anti-cancer ingredient
10 September, 2002 by Melissa TrudingerWestern Australian horticulture company Bioscience has been commissioned by Solbec Pharmaceuticals to set up and run Solbec's horticultural production facility, used to produce its lead anti-cancer compound from Solanum linnaeanum, or devil's apple.
Lucre for Bioglobal's LuciLure
10 September, 2002 by Melissa TrudingerBioglobal has signed an exclusive three-year agreement to market and distribute its LuciLure blowfly trap for sheep protection and landfill markets in Australia and New Zealand.
Novogen claims success in heart drug trial
10 September, 2002 by Graeme O'NeillSydney pharmaceutical company Novogen says the first human clinical trial of its candidate heart-disease therapeutic NV-04 has confirmed the "outstanding potency" it showed in initial trials in laboratory animals.
